No Data
No Data
Kymera Therapeutics to Unveil New Oral Development Candidate
Kymera Therapeutics to Unveil New Oral Immunology Program and Report First Quarter 2025 Financial Results on May 9, 2025
Leerink Partners Sticks to Its Buy Rating for Kymera Therapeutics (KYMR)
Here's Why We're Watching Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Situation
Kymera Therapeutics Initiates Dosing In BroADen Phase 1B Clinical Trial Evaluating KT-621, Potent Degrader Of STAT6, In Patients With Moderate To Severe Atopic Dermatitis
Express News | Kymera Therapeutics Inc - Phase 2B Trials in Ad and Asthma to Start in 4Q25 and 1Q26